<DOC>
	<DOCNO>NCT00523809</DOCNO>
	<brief_summary>The goal clinical research study learn give Avastin ( bevacizumab ) standard chemotherapy blood stem cell transplant , patient advance solid tumor , help shrink tumor slow growth . The safety treatment also study .</brief_summary>
	<brief_title>Allogeneic Hematopoietic Stem Cell Transplantation With Bevacizumab Advanced Solid Tumor</brief_title>
	<detailed_description>The Study Drugs : Bevacizumab design prevent slow growth cancer cell block growth blood vessel . The combination standard chemotherapy drug ( fludarabine melphalan ) use study may help improve chance body accept stem cell transplant . Fludarabine design make cancer cell less able repair damage DNA ( genetic material cell ) weaken immune system stem cell stay body . Melphalan design damage cancer cell ' DNA . Study Drug Administration : If find eligible take part study , central venous catheter insert . A central venous catheter sterile flexible tube place large vein local anesthesia . Your doctor explain procedure detail , require sign separate consent form procedure . You receive chemotherapy bevacizumab , fludarabine , melphalan order prepare stem cell transplant . On Day 1 , receive bevacizumab needle vein 30 minute . On Days 2-6 , receive fludarabine vein 30 minute . On Day 5-6 , receive melphalan vein 30 minute . On Day 7 , receive study drug . Stem Cell Transplant Post-Transplant Drug Administration : On Day 8 , stem cell transplant . Your study doctor explain procedure detail sign separate consent form . After transplant , receive drug tacrolimus methotrexate . Tacrolimus methotrexate use prevent graft versus host disease ( GVHD ) , condition occurs transplant cell attack normal cell body . Tacrolimus give vein non-stop ( 24 hour day ) able take medication mouth . Once able take medication mouth , doctor tell take oral medication . You receive tacrolimus 2-3 month . During last month tacrolimus give , dose lower gradually . Methotrexate give vein second Days 9 , 11 , 14 . An additional dose methotrexate give Day 19 donor parent , child , unrelated family member . If GVHD occur , GVHD treat methylprednisolone vein mouth , need . You may also give steroid cream use skin , need . Starting least 3 week transplant , soon blood count recover , receive bevacizumab every 2 week vein 30 minute . Post-Transplant Procedures : You must stay hospital 3-4 week begin Day 1 . While hospital , blood ( 2 teaspoon ) draw routine test every day . You must stay Houston area 100 day transplant . Once month 100 day transplant , every 3 month first year , scan check status disease . The study doctor decide scan necessary ( chest x-ray , CT scan , and/or bone scan ) . You may also bone marrow aspirate biopsy time . The bone marrow aspirate biopsy would perform bone marrow show involved disease time screen . If disease still present 2 month transplant , GVHD , stop receive tacrolimus within 2 week . After , disease still present another 6 week , GVHD , may receive infusion donor lymphocyte ( type white blood cell ) vein 30 minute . This treatment white blood cell may repeat 2 time 6 week infusion . Length Study : You take off-study 1 year . Follow-Up Visits : You follow-up visit per standard care . This investigational study . The use bevacizumab transplant patient FDA approve . Melphalan fludarabine FDA approve commercially available transplant patient . Up 18 patient take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>1 . From Age 18 Age &lt; /= 65 year old . 2 . Patients must one follow disease . 1 ) metastatic breast cancer achieve tumor response ( complete response ( CR ) partial response ( PR ) ) pretransplant therapy . For bone metastatic breast cancer , tumor response stable disease ( SD ) accept . 2 ) low grade advance ovarian cancer 3 ) high grade advance ovarian cancer achieve antitumor response ( CR PR ) pretransplant therapy . 3 . Zubrod performance status &lt; /= 1 . 4 . An HLAmatched ( 6/6 match ) relate donor unrelated donor ( 8/8 match ) willing able donate peripheral blood stem cell ( PBSC ) bone marrow and/or lymphocytes conventional technique . 5 . Requirement prior treatment . For metastatic renal cell carcinoma ( RCC ) two prior treatment , include target therapy ( e.g . Sorafenib Stutent ) . For breast ovarian cancer , one prior treatment include chemotherapy . 6 . Adequate major organ function . 7 . Signed informed consent . 8 . Left ventricular ejection fraction &gt; /= 45 % . Cardiology clearance need patient leave ventricular ejection fraction &lt; 45 % , uncontrolled arrhythmia , symptomatic cardiac disease . 9 . Forced expiratory volume 1 second ( FEV1 ) , Forced vital capacity ( FVC ) , carbon monoxide diffuse capacity ( DLCO ) &gt; /= 50 % predict value . Pulmonary clearance need patient FEV1 , FVC , DLCO &lt; 50 % predict value symptomatic pulmonary disease . 10 . Serum creatinine &lt; /= 2.0 mg/dL , creatinine clearance &gt; 40 mL/min . 11 . Serum bilirubin &lt; /= 1.5 mg/dL , serum glutamicpyruvic transaminase ( SGPT ) &lt; /= 3 * upper limit normal . 1 . Prior history allogeneic stem cell transplantation . 2 . Life expectancy severely limited concomitant illness . 3 . Clinically significant active infection . 4 . HIV infection . 5 . Chronic active hepatitis . 6 . Pregnant lactating woman . 7 . Presence , prior history multiple brain metastasis . If patient prior single brain metastasis treat complete surgical resection stereotactic radiation therapy , radiological image demonstrate recurrence brain edema least 6 month end treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Ovarian Cancer</keyword>
	<keyword>Stem Cell Transplantation</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Melphalan</keyword>
	<keyword>Avastin</keyword>
	<keyword>Thymoglobulin</keyword>
	<keyword>ATG</keyword>
	<keyword>Antithymocyte Globulin</keyword>
	<keyword>Allogeneic Hematopoietic Stem Cell Transplantation</keyword>
	<keyword>AHSCT</keyword>
</DOC>